Bipolar disorder, current episode mixed, moderate
Methodology & AI Transparency ⓘ
Bipolar disorder, current episode mixed, moderate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Bipolar disorder, current episode mixed, moderate is an ICD-10-CM indexed diagnosis (F31.62) within Depression, Bipolar & Mood Disorders.
- 2 Real-world patient consensus: Federal ICD-10-CM code F31.62 categorizes Bipolar disorder, current episode mixed, moderate under Depression, Bipolar & Mood Disorders.
- 3 Typical cash cost range: Differential triage of Bipolar disorder, current episode mixed, moderate (F31.62) utilizes safety/support screening [Bipolar disorder, current episode mixed, moderate F31.62].
- 4 Top reported side effects / signs: Objective lab/clinical target for Bipolar disorder, current episode mixed, moderate: Serum Vitamin D in Bipolar disorder, current episode mixed, moderate (F31.62: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F31.62)) and PHQ-9 Symptom Severity in Bipolar disorder, current episode mixed, moderate (F31.62: Score).
Ask our AI Specialists anything about Bipolar disorder, current episode mixed, moderate
What Is Bipolar disorder, current episode mixed, moderate?
Bipolar disorder, current episode mixed, moderate is an ICD-10-CM indexed diagnosis (F31.62) within Depression, Bipolar & Mood Disorders. Clinical evaluation centers on safety/support screening [Bipolar disorder, current episode mixed, moderate F31.62] alongside serial Serum Vitamin D in Bipolar disorder, current episode mixed, moderate (F31.62: & RBC Folate) tracking (25(OH)D 40 – 65 ng/mL (F31.62)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Bipolar disorder, current episode mixed, moderate (ICD-10 F31.62) is driven by prefrontal-limbic circuit dysregulation [Bipolar disorder, current episode mixed, moderate F31.62]; specialists in Depression, Bipolar & Mood Disorders monitor PHQ-9 Symptom Severity in Bipolar disorder, current episode mixed, moderate (F31.62: Score) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Bipolar disorder, current episode mixed, moderate (F31.62): loss of interest in Bipolar disorder, current episode mixed, moderate (F31.62: or pleasure in)
- • Secondary Bipolar disorder, current episode mixed, moderate clinical sign: persistent low mood, in Bipolar disorder, current episode mixed, moderate (F31.62: emotional flatness, or)
- • Symptom flares in Bipolar disorder, current episode mixed, moderate correlating with Serum Vitamin D in Bipolar disorder, current episode mixed, moderate (F31.62: & RBC Folate) deviation outside 25(OH)D 40 – 65 ng/mL (F31.62)
- • Functional depression & mood impact requiring safety/support screening [Bipolar disorder, current episode mixed, moderate F31.62] evaluation (F31.62)
Bipolar disorder, current episode mixed, moderate Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F31.62 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Vitamin D in Bipolar disorder, current episode mixed, moderate (F31.62: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F31.62) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Bipolar disorder, current episode mixed, moderate (F31.62: Score) | < 4 (clinical remission) (F31.62) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Bipolar disorder, current episode mixed, moderate (F31.62: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F31.62) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bipolar disorder, current episode mixed, moderate
Treatment selection for Bipolar disorder, current episode mixed, moderate depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bipolar disorder, current episode mixed, moderate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed: What a 376-Participant Study Found Conclusions: Lumateperone 42 mg significantly improved symptoms of depression and disease severity in patients with an MDE associated with bipolar I or bipolar II disorder, with or without mixed features. The Journal of clinical psychiatry • 2023-04-24 • Phase III Randomized Trial | N = 376 | 93/100 | PMID 37103915 ↗ |
| Can This Approach Help? Inside the Latest Research on Exercise fails to improve neurocognition in depressed middle-aged and older We found little evidence to support the benefits of an aerobic exercise intervention on neurocognitive performance in patients with MDD. Medicine and science in sports and exercise • 2008-07-15 • Randomized Controlled Trial | N = 49 | 88/100 | PMID 18580416 ↗ |
| Can This Approach Help? Inside the Latest Research on Duration of Adjunctive Antidepressant Maintenance in Bipolar I In a trial involving patients with bipolar I disorder and a recently remitted depressive episode, adjunctive treatment with escitalopram or bupropion XL that continued for 52 weeks did not show a significant benefit as... The New England journal of medicine • 2023-08-03 • Randomized Controlled Trial | N = 90 | 88/100 | PMID 37530824 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Lumateperone for Major Depressive Episodes Associated With Lumateperone at 42 mg/day significantly improved depression symptoms and was generally well tolerated in patients with major depressive episodes associated with both bipolar I and bipolar II disorders. The American journal of psychiatry • 2021-12-15 • Phase III Randomized Trial | N = 188 | 88/100 | PMID 34551584 ↗ |
| Can This Approach Help? Inside the Latest Research on Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results Lumateperone 42-mg treatment adjunctive to lithium or valproate significantly improved depression symptoms and was generally well tolerated in patients with MDEs associated with either bipolar I or bipolar II disorder. Bipolar disorders • 2023-09-15 • Phase III Randomized Trial | N = 176 | 88/100 | PMID 36779257 ↗ |
Bipolar disorder, current episode mixed, moderate Patient Community & “People Like Me” Threads
Filter Bipolar disorder, current episode mixed, moderate community threads and patient logs by age, biological sex, dosage, and treatment duration.